The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …

In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have
shown excellent clinical results. However, even the latest-generation drug-eluting stent has …

Aims: Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds
(BVS) in routine clinical practice are limited. To fill this gap, we report on the early and …

Objectives: The aim of this study was to determine the risk of scaffold thrombosis (ST) after
percutaneous coronary intervention (PCI) with placement of an ABSORB bioresorbable …

Despite major advances in mechanical and pharmacological reperfusion strategies to
improve acute myocardial infarction (MI) injury, substantial mortality, morbidity, and …

Aims: Next to patient characteristics, the lack of a standardised approach for bioresorbable
vascular scaffold (BVS) implantation is perceived as a potential explanation for the …

Objectives: The purpose of this study was to compare the 1-year outcome between
bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic stent (EES) in ST …

The advent of intracoronary stents has greatly increased the safety and applicability of
percutaneous coronary interventions. One of the drawbacks of drug-eluting stents (DES) is …

The introduction of percutaneous treatment of coronary artery stenosis with balloon
angioplasty was the first revolution in interventional cardiology; the advent of metallic …

The management of acute ST-Elevation Myocardial Infarction (STEMI) has rapidly evolved
worldwide during the last two decades with the better understanding of the need for early …